The DOI matches its Crossref record; 275 of the 275 references it cites were found in a registry or an index.
Active immunization against cancer with dendritic cells: The near future
Abstract
DCs are antigen-presenting cells that regulate several components of the immune system. The mature or terminal stage of DC development induces specific T-cell immunity and resistance to experimental tumors in vivo. However, DC maturation is induced by inflammatory and microbial stimuli, so it is unlikely that mature DCs normally present antigens from tumor cells in cancer patients. Accordingly, clinical studies have begun in which DCs are generated ex vivo, charged with tumor antigens, exposed to maturation stimuli and reinfused to immunize patients. This approach has the potential to control responses to cancer antigens in a specific and nontoxic manner, in both vaccination and therapeutic settings. DCs can mobilize several immune resistance mechanisms. These include CD8+ CTLs, CD4+ helper T cells, NK and NKT cells. Each of these lymphocytes recognizes targets through a distinct mechanism and has the capacity to kill tumor cells and release valuable protective cytokines like IFN-γ. CD4+ T cells also provide essential help for the expansion and maintenance of CD8+ cytolytic cells, while NK and NKT cells can eliminate targets that dampen presentation on MHC class I to escape CTL recognition. The stimulation and concerted action of these classes of lymphocytes can now be studied directly in patients, using ex vivo–derived DCs. Several findings have emerged from studies of healthy volunteers who have been immunized with DCs charged with model antigens, KLH protein and influenza virus matrix peptide. Mature DCs elicit a polarized Th1 type of CD4 T-cell response, only a single injection being required. Vaccination with antigen-bearing DCs also markedly improves the functional affinity of CD8+ T cells. These findings are important in the context of immunotherapy because Th1 cells are more efficient helper cells in experimental models of viral infection and tumors, while high-affinity CTLs should improve recognition of tumor-derived peptides. An important caution also has surfaced when DCs are not adequately differentiated. Immature DCs can silence adaptive T-cell responses, e.g., by inducing IL-10–producing, T-reg cells. DC-based active immunization does not result in major short-term toxicity in healthy subjects or cancer patients. Tumor-specific T-cell responses have been induced and detected in fresh blood specimens without the need for restimulation in vitro. However, the immune responses observed in the first protocols are still smaller than those seen naturally in acute viral infections. Occasional clinical regressions have been noted in these initial feasibility studies, particularly in melanomas, pediatric tumors, lymphomas, prostate cancers and renal cell cancers. This information, coupled with progress in DC biology, suggests many ways to improve the efficacy of this new therapy. Some relevant topics include antigen loading and DC maturation procedures, frequency and route of DC injection, efficiency of DC homing to lymphoid tissues and their longevity once there and the role of distinct DC subsets. A valuable positive control in active immunization protocols is to include an aliquot of DCs pulsed with a viral peptide to verify that the DCs and the patient's immune system are measurably competent. Most of the first vaccination protocols have used DCs charged with synthetic, HLA-binding tumor peptides. Many methods are in place to allow DCs to process a broader array of peptides appropriate for the patient's MHC haplotype. These include transfection (RNA, DNA and viral vectors), select pathways of adsorptive endocytosis, exosomes and tumor cell fusion. An intriguing new approach involves the processing of whole tumor cells. Immature DCs are able to internalize tumor cells, including melanoma, EBV lymphoma and prostate carcinoma cell lines. Following maturation, the processing of tumor cells leads to presentation of multiple epitopes on both MHC class I and II products of DCs. Basic issues in human cancer immunology can be investigated with ex vivo–based DC immunization. Some topics for the near future are the extent to which tumor-specific tolerance is an obstacle to immune therapy and the need to mobilize several adaptive and innate mechanisms in tandem, including Th1 type CD4+ helper T, NK and NKT cells. Progress is also being made in manipulating DCs directly in vivo. This will help to design vaccine adjuvants that improve presentation of tumor cells in patients. Although tumors challenge the immune system in formidable ways relative to infectious diseases, it is now feasible to use active immunotherapy and DC biology to manipulate and study the human response to cancer. CTL, cytolytic T lymphocyte; DC, dendritic cell; EBV, Epstein-Barr virus; KAR, killer activating receptor; KIR, killer inhibitory receptor; KLH, keyhole limpet hemocyanin; MAb, monoclonal antibody; NK, natural killer; NKT cell, natural killer T cell; ODN, oligodeoxynucleotide; TRAIL, TNF-related apoptosis-inducing ligand; TRANCE, TNF-
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kugler, A., Stuhler, G., Walden, P., Zöller, G., Zobywalski, A., Brossart, P., Trefzer, U., Ullrich, S., Müller, C. A., Becker, V., et al. (2000) · Nature Medicine · doi:10.1038/73193 · Cited by 639
RetractedImmunobiology of Dendritic Cells
Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.-J., Pulendran, B., & Palucka, K. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.767 · Cited by 6,634
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862
Oppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00070-4 · Cited by 2,822
In search of the ‘missing self’: MHC molecules and NK cell recognition
Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
Sallusto, F., Cella, M., Danieli, C., & Lanzavecchia, A. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.389 · Cited by 2,500
DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells
Geijtenbeek, T. B. H., Kwon, D. S., Torensma, R., van Vliet, S. J., van Duijnhoven, G. C. F., Middel, J., Cornelissen, I. L. M. H. A., Nottet, H. S. L. M., KewalRamani, V. N., Littman, D. R., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)80694-7 · Cited by 2,447
Cited by
Escudier, B., Dorval, T., Chaput, N., André, F., Caby, M.-P., Novault, S., Flament, C., Leboulaire, C., Borg, C., Amigorena, S., et al. (2005) · Journal of Translational Medicine · doi:10.1186/1479-5876-3-10 · Cited by 1,280
Systemic effects of local radiotherapy
Formenti, S. C., & Demaria, S. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70082-8 · Cited by 1,021
The use of dendritic cells in cancer immunotherapy
Schuler, G., Schuler-Thurner, B., & Steinman, R. M. (2003) · Current Opinion in Immunology · doi:10.1016/s0952-7915(03)00015-3 · Cited by 631
Self-citationHuman lung cancer cells express functionally active Toll-like receptor 9
Droemann, D., Albrecht, D., Gerdes, J., Ulmer, A. J., Branscheid, D., Vollmer, E., Dalhoff, K., Zabel, P., & Goldmann, T. (2005) · Respiratory Research · doi:10.1186/1465-9921-6-1 · Cited by 340
Banerjee, D. K., Dhodapkar, M. V., Matayeva, E., Steinman, R. M., & Dhodapkar, K. M. (2006) · Blood · doi:10.1182/blood-2006-03-011353 · Cited by 311
Self-citation
Metadata
- Authors
- Steinman, R. M., & Dhodapkar, M.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2001-11-15
- Volume
- 94
- Issue
- 4
- Pages
- 459-473
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2000749507
- Cited by
- 299
- References
- 275
- FWCI
- 12.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Active immunization against cancer with dendritic cells: The near future. https://app.cochat.ai/papers/10.1002/ijc.1503
- The paper
- Steinman, R. M., & Dhodapkar, M. (2001). Active immunization against cancer with dendritic cells: The near future. International Journal of Cancer. https://doi.org/10.1002/ijc.1503
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.